Commercial partnership will expand access to Digostics’ innovative oral glucose tolerance testing platform, building on existing regulatory approvals in the UAE and Qatar
Didcot, United Kingdom – 14 September 2026 – Digostics, the digital diagnostics company transforming access to oral glucose tolerance testing (OGTT), today announced a commercial partnership with Emirix Healthcare to support the expansion of GTT@home across the Middle East.
Emirix Healthcare is a Dubai-based regulatory, commercial and distribution platform that helps international pharmaceutical and medical technology companies enter and scale across regional healthcare markets. Through the partnership, Emirix will support the commercial introduction and adoption of GTT@home, building initially on Digostics’ existing regulatory approvals in the UAE and Qatar and creating a platform for wider regional expansion.
GTT@home is the world’s first commercially available solution designed to transform the delivery of the gold-standard oral glucose tolerance test. By digitising and simplifying a test that has traditionally been complex and resource-intensive to deliver, the platform enables healthcare providers to make OGTT testing more accessible, scalable and convenient for patients.
Arif Govani, CEO, Digostics, said:
“The Middle East represents an important growth market for Digostics, with increasing demand for more accessible and scalable approaches to diabetes testing. Emirix combines strong regional expertise with the regulatory, commercial and distribution capabilities needed to turn that opportunity into meaningful adoption. This partnership is an important step in our international growth strategy and in taking GTT@home to many more patients and healthcare providers.”
Diabetes represents a major and growing health challenge across the region. The OGTT remains the gold-standard test for identifying diabetes and gestational diabetes in a number of important clinical settings, yet traditional delivery can place significant demands on patients and healthcare systems. Digostics’ technology is designed to overcome many of these barriers while maintaining the diagnostic integrity of the OGTT.
The platform builds on Digostics’ experience working with NHS organisations in the UK, where GTT@home has been used to support more accessible and operationally resilient glucose tolerance testing pathways.
Menassie Taddese, Chairman & CEO, Emirix Healthcare, said:
“There is a clear need across the region for technologies that can improve access to high-quality diabetes diagnostics while making testing easier to deliver at scale. GTT@home is a differentiated solution with the potential to address an important clinical and operational need. We are delighted to partner with Digostics and look forward to supporting its adoption across the markets we serve.”
The partnership forms part of Digostics’ broader strategy to accelerate international commercialisation of GTT@home through experienced regional partners. Digostics and Emirix will initially focus on establishing the service within approved markets before exploring opportunities for wider geographical expansion.
Jihad Fakhreddine, CEO MEA Digostics, said:
“Our ambition is much bigger than launching in individual markets. We want to create a scalable international model that allows healthcare systems around the world to deliver gold-standard glucose tolerance testing more effectively. Emirix gives us a strong platform from which to build that presence across the Middle East, and we see significant potential for the partnership to grow over time.”
